



Bronchiectasis management in adults: state of the art and future directions

Hayoung Choi ¹, Pamela J. McShane², Stefano Aliberti ^{3,4} and James D. Chalmers ⁵

¹Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea. ²Division of Pulmonary and Critical Care, University of Texas Health Science Center at Tyler, Tyler, TX, USA. ³Department of Biomedical Sciences, Humanitas University, Milan, Italy. ⁴Respiratory Unit, IRCCS Humanitas Research Hospital, Milan, Italy. ⁵Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.

Corresponding author: James D. Chalmers (jchalmers@dundee.ac.uk)



Shareable abstract (@ERSpublications)

Bronchiectasis is a rapidly developing field. This state of the art review highlights recent advancements in bronchiectasis management and emerging therapies. <https://bit.ly/3yiipC0>

Cite this article as: Choi H, McShane PJ, Aliberti S, *et al.* Bronchiectasis management in adults: state of the art and future directions. *Eur Respir J* 2024; 63: 2400518 [DOI: 10.1183/13993003.00518-2024].

This extracted version can be shared freely online.

Copyright ©The authors 2024.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 14 March 2024
Accepted: 8 May 2024

Abstract

Formerly regarded as a rare disease, bronchiectasis is increasingly recognised. A renewed interest in this disease has led to significant progress in bronchiectasis research. Randomised clinical trials (RCTs) have demonstrated the benefits of airway clearance techniques, inhaled antibiotics and long-term macrolide therapy in bronchiectasis patients. However, the heterogeneity of bronchiectasis remains one of the most challenging aspects of management. Phenotypes and endotypes of bronchiectasis have been identified to help find “treatable traits” and partially overcome disease complexity. The goals of therapy for bronchiectasis are to reduce the symptom burden, improve quality of life, reduce exacerbations and prevent disease progression. We review the pharmacological and non-pharmacological treatments that can improve mucociliary clearance, reduce airway inflammation and tackle airway infection, the key pathophysiological features of bronchiectasis. There are also promising treatments in development for the management of bronchiectasis, including novel anti-inflammatory therapies. This review provides a critical update on the management of bronchiectasis focusing on treatable traits and recent RCTs.

